Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer
Abstract Ovarian cancer (OvCa) is the sixth most common gynaecological cancer in the UK, accounting for over 200,000 deaths worldwide. Cancerous Inhibitor of Phosphatase 2 A (CIP2A) is an oncoprotein and an endogenous inhibitor of PP2A. CIP2A is a key regulator for cellular processes (e.g. prolifera...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-05013-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849335343257485312 |
|---|---|
| author | Alice Filipe Sayeh Saravi Denis Mustafov Suzana Panfilov Simran Banger Seyedehnajmeh Mousavikivaj Maria Braoudaki Senthilkumar Kailasam Yasser Riazalhosseini Michelle A. Sahai Fotios Drenos Cristina Sisu Emmanouil Karteris |
| author_facet | Alice Filipe Sayeh Saravi Denis Mustafov Suzana Panfilov Simran Banger Seyedehnajmeh Mousavikivaj Maria Braoudaki Senthilkumar Kailasam Yasser Riazalhosseini Michelle A. Sahai Fotios Drenos Cristina Sisu Emmanouil Karteris |
| author_sort | Alice Filipe |
| collection | DOAJ |
| description | Abstract Ovarian cancer (OvCa) is the sixth most common gynaecological cancer in the UK, accounting for over 200,000 deaths worldwide. Cancerous Inhibitor of Phosphatase 2 A (CIP2A) is an oncoprotein and an endogenous inhibitor of PP2A. CIP2A is a key regulator for cellular processes (e.g. proliferation, DNA damage) and is involved in the progression of many malignancies. In this study we provide a comprehensive overview of its role in OvCa making use of in silico tools, clinical samples and in vitro models. CIP2A is overexpressed in OvCa patients, with metastatic patients having significantly higher expression when compared to patients with malignant and benign ovarian tumours. High CIP2A expression reduces both overall-and progression-free survival, whereas an R530T mutation is predicted to cause structural destabilisation of the CIP2A dimer. We also provide evidence for microRNA (miRNA) and mRNA target interactions with CIP2A. Finally, we have studied the effects of CIP2A inhibition in an in vitro BRCA2 model compared to BRCA2 wild-type OvCa cells, using RNA-sequencing. Gene enrichment pointed towards changes p53 pathway, protein metabolism, transporter activity, DNA replication, and cell cycle. Our data provide a novel insight into the role of CIP2A in OvCa and the potential of drug repurposing for therapeutic interventions. |
| format | Article |
| id | doaj-art-1c0e94b56aed40b080309c9c1fb02a99 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-1c0e94b56aed40b080309c9c1fb02a992025-08-20T03:45:19ZengNature PortfolioScientific Reports2045-23222025-07-0115111510.1038/s41598-025-05013-0Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancerAlice Filipe0Sayeh Saravi1Denis Mustafov2Suzana Panfilov3Simran Banger4Seyedehnajmeh Mousavikivaj5Maria Braoudaki6Senthilkumar Kailasam7Yasser Riazalhosseini8Michelle A. Sahai9Fotios Drenos10Cristina Sisu11Emmanouil Karteris12Department of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonSchool of Life and Medical Sciences, University of HertfordshireVictor Phillip Dahdaleh Institute of Genomic Medicine at McGill UniversityVictor Phillip Dahdaleh Institute of Genomic Medicine at McGill UniversityDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of LondonAbstract Ovarian cancer (OvCa) is the sixth most common gynaecological cancer in the UK, accounting for over 200,000 deaths worldwide. Cancerous Inhibitor of Phosphatase 2 A (CIP2A) is an oncoprotein and an endogenous inhibitor of PP2A. CIP2A is a key regulator for cellular processes (e.g. proliferation, DNA damage) and is involved in the progression of many malignancies. In this study we provide a comprehensive overview of its role in OvCa making use of in silico tools, clinical samples and in vitro models. CIP2A is overexpressed in OvCa patients, with metastatic patients having significantly higher expression when compared to patients with malignant and benign ovarian tumours. High CIP2A expression reduces both overall-and progression-free survival, whereas an R530T mutation is predicted to cause structural destabilisation of the CIP2A dimer. We also provide evidence for microRNA (miRNA) and mRNA target interactions with CIP2A. Finally, we have studied the effects of CIP2A inhibition in an in vitro BRCA2 model compared to BRCA2 wild-type OvCa cells, using RNA-sequencing. Gene enrichment pointed towards changes p53 pathway, protein metabolism, transporter activity, DNA replication, and cell cycle. Our data provide a novel insight into the role of CIP2A in OvCa and the potential of drug repurposing for therapeutic interventions.https://doi.org/10.1038/s41598-025-05013-0 |
| spellingShingle | Alice Filipe Sayeh Saravi Denis Mustafov Suzana Panfilov Simran Banger Seyedehnajmeh Mousavikivaj Maria Braoudaki Senthilkumar Kailasam Yasser Riazalhosseini Michelle A. Sahai Fotios Drenos Cristina Sisu Emmanouil Karteris Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer Scientific Reports |
| title | Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer |
| title_full | Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer |
| title_fullStr | Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer |
| title_full_unstemmed | Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer |
| title_short | Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer |
| title_sort | emerging roles of the cancerous inhibitor of protein phosphatase 2a cip2a in ovarian cancer |
| url | https://doi.org/10.1038/s41598-025-05013-0 |
| work_keys_str_mv | AT alicefilipe emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT sayehsaravi emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT denismustafov emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT suzanapanfilov emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT simranbanger emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT seyedehnajmehmousavikivaj emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT mariabraoudaki emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT senthilkumarkailasam emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT yasserriazalhosseini emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT michelleasahai emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT fotiosdrenos emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT cristinasisu emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer AT emmanouilkarteris emergingrolesofthecancerousinhibitorofproteinphosphatase2acip2ainovariancancer |